Genmab and BioNTech to take BAbs all the way in crowded immuno-oncology

Two European science-driven companies that retain ambitions to grow into independent sales-based pharmaceutical firms are to collaborate in immuno-oncology. Genmab and BioNTech (which also recently announced a separate deal with Eli Lilly) announced on 19 May that they would jointly research, develop and commercialize bispecific antibody (BAb) products. Both firms told Scrip that they had each the will and resources to commercialize any resultant products without licensing out to larger pharmaceutical third-parties.

Two European science-driven companies that retain ambitions to grow into independent sales-based pharmaceutical firms are to collaborate in immuno-oncology. Genmab and BioNTech (which also recently announced a separate deal with Eli Lilly) announced on 19 May that they would jointly research, develop and commercialize bispecific antibody (BAb) products. Both firms told Scrip that they had each the will and resources to commercialize any resultant products without licensing out to larger pharmaceutical third-parties.

The deal funnels some 200 of BioNTech's well-characterized proprietary antibodies through Genmab's DuoBody technology platform to produce bispecific antibodies with...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.